POLE-mutated Endometrial "Carcinosarcoma"
- PMID: 38833721
- DOI: 10.1097/PGP.0000000000001039
POLE-mutated Endometrial "Carcinosarcoma"
Abstract
The molecular subtype classification of endometrial carcinomas has conceptually changed our approach to this disease. However, open questions remain about how to integrate certain histotype diagnoses with the molecular subtype. We report 2 cases with morphologic suspicion for endometrial carcinosarcoma, that still fell short of the essential criteria for diagnosing carcinosarcoma. On subsequent molecular testing pathogenic POLE mutations were detected and a descriptive diagnosis of endometrial endometrioid carcinomas, low-grade with a homologous sarcoma component was rendered. This challenges the existence of POLE-mutated "carcinosarcoma."
Copyright © 2024 by the International Society of Gynecological Pathologists.
Conflict of interest statement
M.K. is a consultant for HelixBiopharma, outside the scope of this study. The remaining authors declare no conflict of interest.
Similar articles
-
Endometrial Carcinosarcomas are Almost Exclusively of p53abn Molecular Subtype After Exclusion of Mimics.Int J Gynecol Pathol. 2024 Sep 1;43(5):506-514. doi: 10.1097/PGP.0000000000001010. Epub 2024 Feb 2. Int J Gynecol Pathol. 2024. PMID: 38303106 Free PMC article.
-
p53 Abnormal (Copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable From Serous Carcinoma.Int J Gynecol Pathol. 2024 Sep 1;43(5):515-526. doi: 10.1097/PGP.0000000000001012. Epub 2024 May 9. Int J Gynecol Pathol. 2024. PMID: 39164940
-
Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.Hum Pathol. 2018 Feb;72:100-106. doi: 10.1016/j.humpath.2017.11.006. Epub 2017 Nov 11. Hum Pathol. 2018. PMID: 29133142
-
Molecular Genetics of Endometrial Carcinoma.Annu Rev Pathol. 2019 Jan 24;14:339-367. doi: 10.1146/annurev-pathol-020117-043609. Epub 2018 Oct 17. Annu Rev Pathol. 2019. PMID: 30332563 Review.
-
The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.PLoS One. 2022 Feb 9;17(2):e0263585. doi: 10.1371/journal.pone.0263585. eCollection 2022. PLoS One. 2022. PMID: 35139130 Free PMC article.
References
-
- Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113:299–310.
-
- Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res 2016;22:4215–4224.
-
- Köbel M, Nelson GS. Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538-549. J Pathol 2018;245:249–250.
-
- Bosse T. The best of both worlds: combining the molecular and traditional (histotype/grade) endometrial cancer classification. AJSP 2022;27:179–186.
-
- Köbel M. Counterpoint: integration of molecular subtype and histotype/grade into one classification system for endometrial carcinoma. AJSP 2022;27:187–197.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources